Search

Your search keyword '"Sarid, Nadav"' showing total 154 results
Start Over Author "Sarid, Nadav"
154 results on '"Sarid, Nadav"'

2. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Author

Avivi, Irit, Perry, Chava, Segman, Yafit, Amit, Odelia, Bar-On, Yaeli, Katz, Ofrat Beyer, Gold, Ronit, Ribakovsky, Elena, Avigdor, Abraham, Vainstein, Vladimir, Goldschmidt, Neta, Ringelstein-Harlev, Shimrit, Horowitz, Netanel A., Gutwein, Odit, Gurion, Ronit, Itchaki, Gilad, Abadi, Uri, Nemets, Anatoly, Sofer, Orit, Vezker, Miri, Tadmor, Tamar, Dally, Najib, Filanovsky, Kalman, Leiba, Merav, Sarid, Nadav, Benyamini, Noam, Luttwak, Efrat, Herishanu, Yair, and Ram, Ron

Published
2022
Full Text
View/download PDF

4. A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma

Author

Bairey, Osnat, primary, Taliansky, Alisa, additional, Glik, Amir, additional, Amiel, Alexandra, additional, Yust‐Katz, Shlomit, additional, Gurion, Ronit, additional, Zektser, Miri, additional, Porges, Tzvika, additional, Sarid, Nadav, additional, Horowitz, Netanel A., additional, Shina, Tzahala Tzuk, additional, Lebel, Eyal, additional, Cohen, Amos, additional, Geiger, Karyn Revital, additional, Raanani, Pia, additional, Wolach, Ofir, additional, and Siegal, Tali, additional

Published
2023
Full Text
View/download PDF

8. Clinically Complex LRBA Deficiency Due to a Founder Allele in the Georgian Jewish Population

Author

Freund, Tal, primary, Baxter, Sarah K., additional, Walsh, Tom, additional, Golan, Hana, additional, Kapelushnik, Joseph, additional, Abramsohn-Goldenberg, Michal, additional, Benor, Shira, additional, Sarid, Nadav, additional, Ram, Ron, additional, Alcalay, Yifat, additional, Segel, Reeval, additional, Renbaum, Paul, additional, Stepensky, Polina, additional, King, Mary-Claire, additional, Torgerson, Troy R., additional, and Hagin, David, additional

Published
2022
Full Text
View/download PDF

12. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome

Author

Levy, Ilana, primary, Lavi, Avital, additional, Zimran, Eran, additional, Grisariu, Sigal, additional, Aumann, Shlomzion, additional, Itchaki, Gilad, additional, Berger, Tamar, additional, Raanani, Pia, additional, Harel, Reut, additional, Aviv, Ariel, additional, Lavi, Noa, additional, Zuckerman, Tsila, additional, Shvidel, Lev, additional, Jarchowsky, Osnat, additional, Ellis, Martin, additional, Herzog Tzarfati, Katrin, additional, Koren-Michowitz, Maya, additional, Sherf, Yehonatan, additional, Levi, Itai, additional, Sofer, Orit, additional, Shpilberg, Ofer, additional, Dally, Nagib, additional, Suriu, Celia, additional, Braester, Andrei, additional, Ben Barouch, Sharon, additional, Leiba, Merav, additional, Goldstein, Daniela, additional, Sarid, Nadav, additional, Yeganeh, Shay, additional, Halloun, Jabour, additional, Mittelman, Moshe, additional, and Tadmor, Tamar, additional

Published
2021
Full Text
View/download PDF

14. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study

Author

Ram, Ron, primary, Grisariu, Sigal, additional, Shargian-Alon, Liat, additional, Amit, Odelia, additional, Bar-On, Yaeli, additional, Stepensky, Polina, additional, Yeshurun, Moshe, additional, Avni, Batia, additional, Hagin, David, additional, Perry, Chava, additional, Gurion, Ronit, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Gold, Ronit, additional, Glait-Santar, Chen, additional, Kay, Sigi, additional, and Avivi, Irit, additional

Published
2021
Full Text
View/download PDF

16. Toxicity and Efficacy of CAR-T in Patients with DLBCL Above the Age of 70 Years Compare to Younger Patients – a Matched Control Multi-Center Cohort Study

Author

Ram, Ron, primary, Grisariu, Sigal, additional, Shargian, Liat, additional, Amit, Odelia, additional, Bar-On, Yael, additional, Stepansky, Polina, additional, Yeshurun, Moshe, additional, Avni, Batia, additional, Hagin, David, additional, Perry, Chava, additional, Gurion, Ronit, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Gold, Ronit, additional, Kay, Sigi, additional, and Avivi, Irit, additional

Published
2021
Full Text
View/download PDF

17. Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model

Author

Kolomansky, Albert, primary, Kay, Irit, additional, Ben-Califa, Nathalie, additional, Gorodov, Anton, additional, Awida, Zamzam, additional, Sadovnic, Ofer, additional, Ibrahim, Maria, additional, Liron, Tamar, additional, Hiram-Bab, Sahar, additional, Oster, Howard S., additional, Sarid, Nadav, additional, Perry, Chava, additional, Gabet, Yankel, additional, Mittelman, Moshe, additional, and Neumann, Drorit, additional

Published
2020
Full Text
View/download PDF

20. Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice

Author

Kolomansky, Albert, primary, Kaye, Irit, additional, Ben-Califa, Nathalie, additional, Gorodov, Anton, additional, Awida, Zamzam, additional, Sadovnic, Ofer, additional, Ibrahim, Maria, additional, Liron, Tamar, additional, Hiram-Bab, Sahar, additional, Oster, Howard S., additional, Sarid, Nadav, additional, Perry, Chava, additional, Gabet, Yankel, additional, Mittelman, Moshe, additional, and Neumann, Drorit, additional

Published
2020
Full Text
View/download PDF

21. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Author

Segman, Yafit, primary, Ribakovsky, Elena, additional, Avigdor, Abraham, additional, Goldhecht, Yair, additional, Vainstein, Vladimir, additional, Goldschmidt, Neta, additional, Harlev, Shimrit, additional, Horwitz, Netanel, additional, Gutwein, Odit, additional, Gurion, Ronit, additional, Itchaki, Gilad, additional, Abadi, Uri, additional, Nemets, Anatoly, additional, Sofer, Orit, additional, Zektser, Miri, additional, Tadmor, Tamar, additional, Dally, Nagib, additional, Filanovsky, Kalman, additional, Leiba, Merav, additional, Sarid, Nadav, additional, Benyamini, Noam, additional, Herishanu, Yair, additional, Ram, Ron, additional, Perry, Chava, additional, and Avivi, Irit, additional

Published
2020
Full Text
View/download PDF

26. Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Author

Segman, Yafit, primary, Ribakovsky, Elena, additional, Avigdor, Abraham, additional, Vainstein, Vladimir, additional, Goldschmidt, Neta, additional, Harlev, Shimrit Ringelstein, additional, Gutwein, Odit, additional, Abadi, Uri, additional, Nemets, Anatoly, additional, Sofer, Orit, additional, Dally, Najib, additional, Filanovsky, Kalman, additional, Leiba, Merav, additional, Sarid, Nadav, additional, Benyamini, Noam, additional, Herishanu, Yair, additional, Ram, Ron, additional, Perry, Chava, additional, and Avivi, Irit, additional

Published
2019
Full Text
View/download PDF

28. Continuing dilemmas in the management of lymphoma during pregnancy: review of a 10-point case-based questionnaire

Author

Herishanu Yair, Joffe Erel, Sarid Nadav, Lishner Michael, Avivi Irit, Amit Odelia, and Perry Chava

Subjects
medicine.medical_specialty, Pediatrics, medicine.medical_treatment, Follicular lymphoma, Gestational Age, Vinblastine, 03 medical and health sciences, Birth Intervals, 0302 clinical medicine, Pregnancy, Chemoimmunotherapy, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Israel, Practice Patterns, Physicians', Lymphoma, Follicular, Gynecology, Chemotherapy, business.industry, Retrospective cohort study, Hematology, General Medicine, medicine.disease, Hodgkin Disease, Magnetic Resonance Imaging, Lymphoma, Radiation therapy, Review Literature as Topic, Methotrexate, Oncology, 030220 oncology & carcinogenesis, Female, Steroids, Surgery, Lymphoma, Large B-Cell, Diffuse, Pregnancy Trimesters, business, Pregnancy Complications, Neoplastic, 030215 immunology, medicine.drug
Abstract

Due to the rarity of lymphoma during pregnancy, management guidelines are based upon evidence from retrospective studies and case reports. Here, we review the major dilemmas in the field and examine the approach of hemato-oncologists in Israel to the management of lymphoma in pregnancy. We performed a literature search on the PubMed database using keywords for all papers on the subject from 1990−2014. The papers were reviewed by an expert panel who devised a questionnaire covering the main dilemmas. Sixty questionnaires were sent out. Non-contrast magnetic resonance imaging was the staging modality of choice. Chemoimmunotherapy was considered relatively safe beyond the first trimester except methotrexate (completed postpartum). Steroids or vinblastine were suggested by most as a reasonable ‘bridging therapy’ until the second trimester in Hodgkin lymphoma. The dosage of chemoimmunotherapy employed during pregnancy remained debatable; the majority recommended dosage according to actual pregnancy weight. Optimal timing for delivery was considered by most to be >35 weeks. Regarding approach to next pregnancy for patients in complete remission from diffuse large B-cell lymphoma, 69 % advised waiting 2 years but the majority advised 6−12 months for follicular lymphoma. Despite consensus regarding the safety of chemotherapy post first trimester, optimal dosage, central nervous system therapy, timing of delivery and approach to future pregnancies remain controversial, indicating a need for further collaborative research in this field.

Published
2016

29. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study

Author

Perry, Chava, primary, Ben Barouch, Sharon, additional, Goldschmidt, Neta, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Shvidel, Lev, additional, Bairey, Osnat, additional, Lavi, Noa, additional, Horowitz, Netanel, additional, Avigdor, Avraham, additional, Lebel, Eyal, additional, Sofer, Orit, additional, Ram, Ron, additional, and Avivi, Irit, additional

Published
2019
Full Text
View/download PDF

30. Facing erythrocytosis: Results of an international physician survey

Author

Rumi, Elisa, primary, McMullin, Mary F., additional, Harrison, Claire, additional, Ellis, Martin H., additional, Barzilai, Merav, additional, Sarid, Nadav, additional, Mesa, Ruben, additional, Paoli, Chiara, additional, Angona, Anna, additional, Sant'Antonio, Emanuela, additional, Ferretti, Virginia V., additional, Cavalloni, Chiara, additional, Casetti, Ilaria C., additional, Trotti, Chiara, additional, and Barbui, Tiziano, additional

Published
2019
Full Text
View/download PDF

32. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.

Author

Segman, Yafit, Ribakovsky, Elena, Avigdor, Abraham, Goldhecht, Yair, Vainstein, Vladimir, Goldschmidt, Neta, Harlev, Shimrit, Horwitz, Netanel, Gutwein, Odit, Gurion, Ronit, Itchaki, Gilad, Abadi, Uri, Nemets, Anatoly, Sofer, Orit, Zektser, Miri, Tadmor, Tamar, Dally, Nagib, Filanovsky, Kalman, Leiba, Merav, and Sarid, Nadav

Subjects
DIFFUSE large B-cell lymphomas, PROGRESSION-free survival, LYMPHOMAS, HODGKIN'S disease
Abstract

The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymphoma, treated with polatuzumab-based regimen in 14 Israeli centers between June 2018 and November 2019, were included. Median age was 66.1 years (60.4–78.8) and median number of prior lines was 3 (2–7). The overall response rate was 61% (n = 29), including 40% complete responses (n = 19) and 21% (n = 10) partial responses. The median overall survival and progression-free survival were 8.3 months and 5.6 months, respectively. An ECOG PS ≥2 predicted a decreased overall survival (p = 0.045). Primary refractory vs relapsed disease (p = 0.005) and transformed vs de-novo DLBCL (p = 0.039) were associated with shorter PFS (p = 0.027). Our data show that polatuzumab-based regimen is an effective and tolerable treatment in relapsed/refractory DLBCL. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

36. Treatment and prognosis of stage I follicular lymphoma in the modern era – does PET matter?

Author

Bentur, Ohad S., primary, Gurion, Ronit, additional, Gafter-Gvili, Anat, additional, Gatt, Moshe, additional, Shvidel, Lev, additional, Horowitz, Netanel A., additional, Ram, Ron, additional, Herishanu, Yair, additional, Sarid, Nadav, additional, Paltiel, Ora, additional, Ganzel, Chezi, additional, Kreiniz, Natalia, additional, Dally, Najib, additional, Gutwein, Odit, additional, Raanani, Pia, additional, Avivi, Irit, additional, and Perry, Chava, additional

Published
2017
Full Text
View/download PDF

37. CT findings are highly predictive for perforation in patients with diffuse large B-cell lymphoma involving the intestines.

Author

Sarid, Nadav, Sherban, Adi, Herishanu, Yair, Perry, Chava, Avivi, Irit, Bendet, Achiude, and Adam, Sharon

Subjects
*BCL-2 proteins, *LYMPHOMAS, *HODGKIN'S disease, *PROGNOSIS, *CANCER chemotherapy
Abstract

Patients with diffuse large B-cell lymphoma (DLBCL) presenting with intestinal involvement are prone to develop perforation. Identification of those who are at high risk for this complication would enable a rational-based decision regarding preemptive surgery. Although computed tomography (CT) is widely used at diagnosis, data regarding its ability to predict intestinal perforation are scanty. We performed a retrospective single-center study, including all consecutive DLBCL patients presented with intestinal involvement, assessing predictors for perforation with an emphasis on CT-related parameters. Forty-nine patients were included, 43 (88%) underwent CT scan at diagnosis. Ten patients (20%) developed intestinal perforation. A univariate regression analysis found increased risk among patients with a concentric, transmural lesion, and a longer involved intestinal segment. In conclusion, CT scan results can define patients with DLBCL and intestinal involvement who are at risk for perforation, suggesting that a preemptive surgical resection should be considered in these cases. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

40. Comparison of the Low Toxicity Tecam Conditioning Regimen to BEAM in Patients with Lymphoma Requiring Autologous Stem Cell Transplantation

Author

Rosenberg, Dana, primary, Joffe, Erel, additional, Rozovski, Uri, additional, Perry, Chava, additional, Kirgner, Ilya, additional, Trestman, Svetlana, additional, Gur, Odelia, additional, Aviv, Freddy, additional, Sarid, Nadav, additional, Kolomansky, Albert, additional, Gepstein, Lily, additional, Herishanu, Yair, additional, and Naparstek, Elizabeth, additional

Published
2015
Full Text
View/download PDF

42. Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?

Author

Bentur, Ohad S., Sarid, Nadav, Ram, Ron, Herishanu, Yair, Avivi, Irit, Perry, Chava, Kreiniz, Natalia, Dally, Najib, Gurion, Ronit, Raanani, Pia, Gafter-Gvili, Anat, Gutwein, Odit, Gatt, Moshe, Paltiel, Ora, Shvidel, Lev, Ganzel, Chezi, and Horowitz, Netanel A.

Subjects
*LYMPHOMAS, *HODGKIN'S disease, *RADIOTHERAPY, *TOMOGRAPHY, *PROGRESSION-free survival
Abstract

Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma. Patients with stage I disease are usually treated with radiotherapy (RT). In previous studies, mostly from the pre positron emission tomography-computed tomography (PET-CT) era, the 5 year progression-free survival (PFS) and overall survival (OS) rates of stage I disease were 60-80% and 80-93%, respectively. This study retrospectively evaluated the outcome of stage I FL which was treated with involved field RT in the PET-CT era between 2002 and 2015. Ninety-one patients were enrolled. Five year PFS and OS rates were 73% and 97%, respectively. Relapse occurred in 19 (21%) patients, 74% occurring outside the radiation field. In conclusion, PET-CT staging of clinical stage I FL may contribute to the improved prognosis in patients treated with RT compared to historical cohorts, possibly due to better identification of “genuine” stage I disease. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

43. Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study.

Author

Davidov, Marina, Perry, Chava, Herishanu, Yair, Sarid, Nadav, Rom, Esti, Amit, Odelia, Eshel, Rinat, Naparstek, Ella, Avivi, Irit, and Ram, Ron

Subjects
HEMATOPOIETIC stem cell transplantation, LYMPHOMAS, OLDER patients, MUCOSITIS, LUNG diseases, LYMPHOMA treatment, AGE distribution, AUTOGRAFTS, CANCER relapse, CANCER invasiveness, HOSPITAL care, LONGITUDINAL method, TREATMENT effectiveness
Abstract

High-dose therapy followed by autologous hematopoietic cell transplantation (HCT) prolongs overall survival in patients under 65 years old with relapsed aggressive lymphoma. We aimed to explore the toxicity and efficacy of HCT in patients over 65 years with aggressive lymphoma compared with younger patients. We compared the transplantation outcomes between patients ≥ 65 years (n = 58) and 55-64 years (n = 44) with chemosensitive aggressive lymphoma (DLBCL, MCL and TCL) that underwent HCT between 1999 and 2016 in the Tel-Aviv Medical Center. The median age was 68 (range, 65-74) and 61 (range, 55-64) years, respectively. There were no differences in the incidences of grade 3-4 mucositis, documented infections and pulmonary complications between the two groups. There was no difference in the incidences of secondary malignancies, relapse (p = .26), non-relapse mortality, (p = .77) and overall survival (p = .53). Multivariate analysis revealed that smoking was a risk factor for non-relapse mortality, while partial remission and > 2 lines of treatment prior HCT were associated with higher risk for relapse. Psycho-socioeconomic score was associated with prolonged hospitalization after HCT and recurrent hospitalizations. We conclude that patients ≥ 65 years old with aggressive lymphoma, compared to younger counterparts, have similar transplantation outcome. Improving habits and psychosocial factors may further improve outcomes in these patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

46. Reduced-dose ICE chemotherapy ± rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma.

Author

Sarid, Nadav, Joffe, Erel, Gibstein, Lili, Avivi, Irit, Polliack, Aaron, Perry, Chava, and Herishanu, Yair

Subjects
*IFOSFAMIDE, *ANTINEOPLASTIC agents, *CARBOPLATIN, *ETOPOSIDE, *B cell lymphoma, *LYMPHOMAS, *CANCER chemotherapy
Abstract

The risk of developing non-Hodgkin lymphoma increases with age, yet elderly patients are under-represented in clinical trials. Here, we evaluate a combination regimen including ifosfamide, carboplatin and etoposide with or without rituximab (ICE ± R) in 32 fit elderly patients (median age 75.6 years) with relapsed or refractory diffuse large B-cell lymphoma. ICE ± R was generally administered in reduced doses and was well tolerated. The overall response rate (ORR) was 53.1% with a complete response (CR) rate of 40.6%. The median progression free survival (PFS) and overall survival (OS) were 3.9 and 17.0 months, respectively. Patients who responded to ICE ± R achieved median PFS of 47.2 months and OS of 78.9 months. Patients ineligible for autologous transplantation who responded to ICE ± R were treated with additional cycles, and achieved a median PFS of 18.9 months and OS of 21.7 months. Previous response to first-line therapy was the strongest predictor of response, PFS and OS to second-line treatment. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

50. Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia.

Author

Tavor, Sigal, Rothman, Rachel, Golan, Tamar, Voskoboinik, Nadia, Katz, Ben-Zion, Sarid, Nadav, Shomrat, Ruth, Orr-Urtreger, Avi, and Naparstek, Elizabeth

Subjects
ACUTE myeloid leukemia diagnosis, KARYOTYPES, DIAGNOSTIC use of fluorescence in situ hybridization, CHROMOSOME abnormalities, DRUG therapy, PROGNOSIS
Abstract

Acute myeloid leukemia (AML) with a complex karyotype (CK) has frequent alterations in TP53 and a very poor prognosis. We examined whether a prompt and simple fluorescence in situ hybridization (FISH) analysis for 17p13 deletion at diagnosis has a predictive value for response to therapy and overall survival in subgroups of AML. In 15 patients with a normal karyotype the TP53 FISH analysis was normal, whereas in 16 patients with CK 75%% had only one copy of the TP53 allele. The deletion was also detected in 33%% of six patients with monosomy or partial monosomy of chromosome 5, 7, 9, or 12. This loss of TP53 correlated significantly with a poor response to chemotherapy, and the median survival time of these patients was shorter. TP53 FISH analysis carried out at diagnosis has a predictive value with respect to chemotherapy response and can therefore facilitate a rapid decision on treatment strategies. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results